FERRIPROX
As listed in the register: FERRIPROX
500 mg · tablet
- Prescription only
- Everything that fits nowhere else, such as contrast media
- Active substance
- Deferiprone
- Made by
- Chiesi Canada Corp.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Deferiprone). It describes the substance, not this exact product.
Deferiprone is a chelating agent with an affinity for ferric ions (iron III).
Deferiprone binds with ferric ions to form neutral 3:1 (deferiprone:iron) complexes that are stable at physiological pH.
Deferiprone is metabolized primarily by UGT1A6.
Effect of Food No clinically significant differences in the pharmacokinetics of deferiprone were observed following administration with food.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-08-12
Safety of the active substance
From the US prescribing label for the same active substance (Deferiprone). It describes the substance, not this exact product.
WARNING: AGRANULOCYTOSIS AND NEUTROPENIA Deferiprone can cause agranulocytosis that can lead to serious infections and death.
- Deferiprone is contraindicated in patients with known hypersensitivity to deferiprone or to any of the excipients in the formulations.
- The following reactions have been reported in association with the administration of deferiprone: Henoch-Schönlein purpura; urticaria; and periorbital edema with skin rash [see Adverse Reactions (6.2) ].
- Hypersensitivity to deferiprone or to any of the excipients in the formulations.
The most common adverse reactions (≥6%) reported during clinical trials were nausea, vomiting, abdominal pain, arthralgia, alanine aminotransferase increased and neutropenia.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States4 matching products
European UnionNo exact match for this strength and form
Netherlands2 matching products
SwitzerlandNo exact match for this strength and form
Details
| Made by | Chiesi Canada Corp. |
|---|---|
| Active substance | Deferiprone |
| Used in | Everything that fits nowhere else, such as contrast media |
| Strength | 500 mg |
| Form | tablet |
| Classification | V03AC02 · Everything that fits nowhere else, such as contrast media |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02436531 |
| DPD drug code | 92087 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
3 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.